research Erlotinib-related Severe Hair Loss with Severe Exanthematous Drug Eruption: A Case Report
Stopping erlotinib improved severe hair loss and skin issues in a patient.
Search
for
Sort by
Research
360-390 / 1000+ resultsresearch 861 EGFR/MEK inhibitor therapy induces partial hair follicle immune privilege collapse in vivo and ex vivo
research 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
Brepocitinib improves cicatricial alopecia and reduces key immune markers.
research Is It Time to Re-Imagine Clinical Trials in Nephrology?
Metatrials could improve clinical research in nephrology by speeding up data collection and overcoming challenges like patient recruitment.
research Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
research Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
research Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
Cancer treatments often cause skin, nail, and hair problems.
research Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
research An accessible pharmacodynamic transcriptional biomarker for notch target engagement
Hair follicle samples effectively show how well the drug MK-0752 targets and engages with the Notch pathway.
research First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study
Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
research Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
research Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research 046 Analysing the mechanistic basis of Ritlecitinib’s therapeutic effects in Alopecia Areata
Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
research Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
research Primary TSC2-/meth Cells Induce Follicular Neogenesis in an Innovative TSC Mouse Model
TSC2-/meth cells can cause skin lesions, hair growth, and lung issues, and may be treated with chromatin remodeling agents.
research Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)
Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.
research Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
Ruxolitinib effectively and safely regrows hair in alopecia patients.
research Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
research Dual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report
Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
research Topical treatment with the bacterium-derived c-Met agonist InlB321/15 accelerates healing in the abrasion wound mouse model
Applying InlB321/15 to wounds sped up healing in mice.
research Metformin protects against gentamicin-induced hair cell death in vitro but not ototoxicity in vivo
Metformin protects hair cells in lab tests but not in live animals.
research Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review
Upadacitinib effectively treated severe hair loss in a child.
research Folliculitis decalvans associated with erlotinib
Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.
research Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance
Repurposing existing drugs and using micronutrients may effectively target cancer stem cells and improve cancer treatment.
research Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
EGFR-TKIs can cause unexpected skin, nail, and hair issues.
research Systematic review – alopecia areata and tofacitinib in paediatric patients
Tofacitinib may help treat hair loss in children with alopecia areata.
research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.